TSROTopological Short-Range Order
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
As was anticipated when TSRO was set up, the run-down has created an impression that there is no security if one enrols in those arms which, at first sight, may not offer technical qualifications or training in 'trades'.
GlaxoSmithKline (GSK) and TESARO (TSRO) announced that the companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1B.
Tesaro (TSRO), up 59% after GlaxoSmithKline (GSK) announced a definitive agreement to acquire Tesaro for $75 per share.
Cantor Fitzgerald analyst Alethia Young believes Tesaro (TSRO) could be valued at $89-$97 per share in a takeout scenario.
TESARO (TSRO) announced the achievement of development milestones that trigger an $18M payment from Janssen Biotech (JNJ).
Cantor Fitzgerald analyst Alethia Young raised her price target for Tesaro (TSRO) to $68 saying AstraZeneca's (AZN) presented the Solo1 study using olaparib as a first-line treatment for BRCA ovarian cancer patients is positive for Tesaro's first-line study Prima study, with data expected in the second half of 2019.
Results from the study show comparable PK profile of the Chinese patients administered ZL-2306 to that of patients evaluated in Tesaro's (TSRO) global PK study.
Piper Jaffray analyst Christopher Raymond reiterates a Neutral rating and $35 price target on Tesaro (TSRO) after analyzing a year's worth of adverse event reporting as captured by FDA's Adverse Event Reporting System database, which he obtained through a Freedom of Information Act request.
ALSO HIGHER: Tesaro (TSRO) up 10.8% after expanding to 2nd stage of Jasper trial of Zejula in combo with TSR-042...
Tesaro (TSRO) downgraded to Hold from Buy at Argus.
Intereconomia in June reported that Roche (RHHBY) could announce a buyout of Tesaro (TSRO) in the coming days.
Both Tesaro (TSRO) and Clovis have pulled back after initial enthusiasm on the PARP inhibitors as a drug class in oncology, but Wang still sees great potential for PARPi to penetrate broader cancer indications and believes the collective global market opportunity is large enough for multiple players.